Literature DB >> 6800679

Metabolite cumulation during long-term oral encainide administration.

R E Kates, D C Harrison, R A Winkle.   

Abstract

Cumulation of encainide and its major metabolites, O-demethylencainide (ODE), 3-methoxy-ODE (MODE), and N-demethylencainide (NDE) was examined in patients with frequent complex ventricular ectopy. After 6 mo on encainide patients were admitted to Stanford University Hospital and the drug was discontinued for 24 hr. During this time blood samples were drawn to characterize the cumulation and disposition of the drug and metabolites. The mean steady-state concentrations of encainide, ODE, and MODE were 56.3, 214.6, and 184.6 ng/ml after doses ranging from 100 to 250 mg/day. The concentration ratios of ODE/encainide and MODE/encainide were 5.02 +/- 2.61 and 5.15 +/- 4.13. NDE was detected in the plasma of only one patient. Elimination half lifes of encainide and ODE were 1.16 +/- 0.5 and 11.41 +/- 9.58 hr. MODE disappeared slowly and at 24 hr the plasma concentration was still 59.8 +/- 39.9% of its mean steady-state concentration. Our data indicate that the metabolites of encainide cumulate in the plasma of patients on long-term oral therapy and must be considered when evaluating its clinical efficacy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6800679     DOI: 10.1038/clpt.1982.55

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

1.  Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents.

Authors:  P Dayer; L Balant; A Küpfer; F Courvoisier; J Fabre
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Depression of maximum rate of depolarization of guinea-pig ventricular action potentials by metabolites of encainide.

Authors:  P D Hemsworth; T J Campbell
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

Review 3.  Pharmacokinetics and metabolism of encainide.

Authors:  P Jaillon
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

Review 4.  Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.

Authors:  J L Bauman; M D Schoen; T J Hoon
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

5.  Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals.

Authors:  E L Carey; H J Duff; D M Roden; R K Primm; G R Wilkinson; T Wang; J A Oates; R L Woosley
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

Review 6.  Encainide.

Authors:  M J Antonaccio; A W Gomoll; J E Byrne
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 7.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of encainide.

Authors:  D M Roden; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1988-03       Impact factor: 6.447

Review 9.  New antiarrhythmic drugs.

Authors:  P F Nestico; J Morganroth; L N Horowitz
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

10.  Identification of a prazosin metabolite and some preliminary data on its kinetics in hypertensive patients.

Authors:  V K Piotrovskii; N N Veiko; O S Ryabokon; S F Postolnikov; V I Metelitsa
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.